BioNexus Gene Lab (BGLC) Cash & Current Investments (2018 - 2026)

BioNexus Gene Lab has reported Cash & Current Investments for 9 years, with the latest figure at $4.0 million in Q1 2026.

• Quarterly Cash & Current Investments rose 89.76% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 89.76% YoY) and the FY2025 annual result came in at $4.0 million, down 28.89% from the prior year.
• Cash & Current Investments fell to $4.0 million in Q1 2026 per BGLC's latest filing, from $4.0 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $5.8 million in Q1 2024 and troughed at $1.3 million in Q2 2022.
• A 5-year average of $3.2 million and a median of $2.9 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments surged 221.75% in 2023, then tumbled 64.17% in 2025.
• Over 5 years, Cash & Current Investments stood at $2.1 million in 2022, then surged by 113.21% to $4.5 million in 2023, then grew by 25.75% to $5.7 million in 2024, then dropped by 28.89% to $4.0 million in 2025, then slipped by 1.85% to $4.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $4.0 million, $4.0 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.